Although many studies have demonstrated beneficial effects of rapamycin in alleviating AD pathology, including reducing Aβ accumulation [239], tau hyperphosphorylation [240] and neuroinflammation [241], and improving cognitive dysfunction [242], the effects of rapamycin remain controversial. This evidence concerns the gene MAPT and Alzheimer disease.